Determination of Human Fibrinopeptide A by Radioimmunoassay in Purified Systems and in the Blood^[*]

Summary

The formation of fibrin clots or circulating soluble fibrin is accompanied by the appearance of fibrinopeptides. Measurement of the fibrinopeptide concentration in plasma can provide important information on the rate of conversion of fibrinogen to fibrin by thrombin. This rate varies under different physiologic and pathologic conditions. Fibrinopeptide A is a better molecular marker of the conversion than fibrinopeptide B since it is the first peptide to be cleaved by thrombin. A radioimmunoassay technique has been developed for the quantitative determination of human fibrinopeptide A. The procedure detects human fibrinopeptide A at a concentration of approximately 0.05 ng/ml. The fibrinopeptide A concentration in plasma of normal persons was found to be approximately 0.5 ng/ml. The variation of fibrinopeptide A content in normal persons may reflect its rapid formation and catabolism. A significantly increased concentration of this peptide was found in a patient during defibrination therapy with a purified enzyme from the venom of Agkistrodon rho-dostoma and in patients suffering from retinal vascular occlusions.

^* Presented at the Postgraduate Course and Workshop “Progress in Fibrinolysis”, Milano, Italy, March 6–8, 1975.

• References

• 1 Bailey K, Bettelheim F. R, Lorano L, and Middlebrook W. R. 1951; Action of thrombin in the clotting of fibrinogen. Nature (London) 167: 233.
• 2 Bettelheim F. R, and Bailey K. 1952; The products of the action of thrombin on fibrinogen. Biochimica Biophysica Acta 9: 578.
• 3 Blombäck B, Blombäck M, Edman P, and Hessel B. 1966; Human fibrinopeptides. Isolation, characterization and structure. Biochimica Biophysica Acta 115: 371.
• 4 Blombäck B, and Yamashina I. 1958; On the N-terminal amino acids in fibrinogen and fibrin. Arkiv Kemi 12: 299.
• 5 Budzynski A. Z. 1969; Structure of fibrinogen in relation to its proteolytic degradation products. Postepy Higieny i Medycyny Doswiadczalnej 23: 293.
• 6 Budzynski A. Z, Marder V. J, and Shainoff J. R. 1974; Structure of plasmic degradation products of human fibrinogen. Fibrinopeptide and polypeptide chain analysis. Journal of Biological Chemistry 249: 2294.
• 7 Budzynski A. Z, and Marder V. J. 1973; Solid phase synthesis of human fibrinopeptides A and B. Protides of Biological Fluids 20: 287.
• 8 Budzynski A. Z, Marder V. J, and Sherry S. 1975; Reaction of plasmic degradation products of fibrinogen in the radioimmunoassay of human fibrinopeptide A. Blood 45: 757.
• 9 Dayhoff M. O. 1972 Atlas of Protein Sequence and Structure. National Biomedical Research Foundation, Silver Spring, Maryland. Vol. 5, pp. D 95, D 96.
• 10 Fletcher A. P, Alkjaersig N, O’Brien J, and Tulevski V. G. 1970; Blood hypercoagulability and thrombosis. Transactions of the Association of American Physicians 83: 159.
• 11 Fletcher A. P, Alkjaersig N, and Sherry S. 1962; Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. I. The significance of fibrinogen proteolysis and circulating fibrinogen breakdown products. Journal of Clinical Investigations 41: 896.
• 12 Folk J. E, Gladner J. A, and Laki K. 1959; The thrombin induced formation of co-fibrin. II. Preliminary amino acid sequence studies on peptides A and B. Journal of Biological Chemistry 234: 67.
• 13 Gerrits W. B. J, Flier O. T. N, and van der Meer J. 1974; Fibrinopeptide A immunoreactivity in human plasma. Thrombosis Research 5: 197.
• 14 Gladner J. A, Folk J. E, Laki K, and Carroll W. R. 1959; Thrombin-induced formation of co-fibrin. I. Isolation, purification and characterization of co-fibrin. Journal of Biological Chemistry 234: 62.
• 15 Hunter W. M, and Greenwood F. C. 1962; Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194: 495.
• 16 Lahiri B, and Shainoff J. R. 1972; Fate of fibrinopeptides in the reaction between human plasmin and fibrinogen. Biochimica Biophysica Acta 303: 161.
• 17 Larrieu M. J, Marder V. J, and Inceman S. 1966; Effects of fibrinogen degradation products on platelets and coagulation. Thrombosis et Diathesis Haemorrhagica Suppl.20: 215.
• 18 Larrieu M. J, Rigollot C, and Marder V. J. 1972; Comparative effects of fibrinogen degradation Fragments D and E on coagulation. British Journal of Haematology 22: 719.
• 19 Latallo Z. S, Fletcher A. P, Alkjaersig N, and Sherry S. 1962; Inhibition of fibrin polymerization by fibrinogen proteolysis products. American Journal of Physiology 202: 681.
• 20 Latallo Z. S, Budzynski A. Z, Lipinski B, and Kowalski E. 1964; Inhibition of thrombin and of fibrin polymerization, two activities derived from plasmin-digested fibrinogen. Nature 203: 1184.
• 21 Lipinski B, Wegrzynowicz Z, Budzynski A. Z, Kopec M, Latallo Z. S, and Kowalski E. 1967; Soluble unclottable complexes formed in the presence of fibrinogen degradation products (FDP) during the fibrinogen-fibrin conversion and their potential significance in pathology. Thrombosis et Diathesis Haemorrhagica 17: 65.
• 22 Lorano L. 1952; Fibrino-peptide. Biochemical Journal 52: 200.
• 23 Marder V. J, and Budzynski A. Z. 1971; Classification of fibrinogen derivatives. Thrombosis et Diathesis Haemorrhagica Suppl.51: 267.
• 24 Marder V. J, and Budzynski A. Z. 1975; Data for defining fibrinogen and its plasmic degradation products. Thrombosis et Diathesis Haemorrhagica 33: 199.
• 25 Marder V. J, Shulman N. B, and Carroll W. B. 1969; a High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. Journal of Biological Chemistry 244: 2111.
• 26 Marder V. J, Shulman N. B. 1969; b High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. Journal of Biological Chemistry 244: 2120.
• 27 Marshall G. B, and Merrifield R. B. 1965; Synthesis of angiotensins by the solid-phase method. Biochemistry 4: 2394.
• 28 Merrifield R. B. 1963; Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. Journal of the American Chemistry Society 85: 2149.
• 29 Merrifield R. B. 1964; Solid phase peptide synthesis. III. An improved synthesis of bradykinin. Biochemistry 3: 1385.
• 30 Nossel H. L, Younger L. R, Wilner G. D, Procupez T, Canfield R. E, and Butler Jr. V. P. 1971; Radioimmunoassay of human fibrinopeptide A. Proceedings of the National Academy of Sciences 68: 2350.
• 31 Nossel H. L, Yudelman L, Canfield R. E, Butler Jr. V. P, Spanondis K, Wilner G. D, and Qureshi G. D. 1974; Measurement of fibrinopeptide A in human blood. Journal of Clinical Investigation 54: 43.
• 32 Schick A. F, and Singer S. J. 1961; On the formation of covalent linkages between two protein molecules. Journal of Biological Chemistry 236: 2477.
• 33 Shainoff J. R, Lahiri B, and Bumpus F. M. 1970; Ultracentrifuge studies on the reaction between thrombin and plasminized fibrinogen. Thrombosis et Diathesis Haemorrhagica 39: 203.
• 34 Shainoff J. R, and Page I. H. 1960; Cofibrins and fibrin-intermediates as indicators of thrombin activity, in vivo. Circulation Research 8: 1013.
• 35 Smith G. F, and Bang N. U. 1972; Formation of soluble fibrin polymers. Fibrinogen degradation fragments D and E fail to form soluble complexes with fibrin monomer. Biochemistry 11: 2958.
• 36 Wessler S, and Stehbens W. E. 1971. Thrombosis. In: Bang N. U, Beller F. K, Deutsch E, and Mammen E. F. (eds.) Thrombosis and Bleeding Disorders. Academic Press; New York: 488.